Tides of inflammation: impact of biologics.
Increased knowledge about the mechanisms of joint inflammation and damage has profoundly shaped the development of new therapies for rheumatoid arthritis (RA). The first stop on this remarkable bench-to-bedside journey has been the biologics targeting tumor necrosis factor-alpha (TNF-alpha) and interleukin 1 (IL-1). These engineered adaptations of naturally occurring molecules function to neutralize the biological activity of proinflammatory cytokines overproduced in the joints of patients with RA. The successful translation of this approach into the clinic has had a substantial effect on the care of patients with RA.
St Clair
E William
EW
stc1003@mc.duke.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D053590:Interleukin 1 Receptor Antagonist Protein; D008297:Male; D010147:Pain Measurement; D016059:Range of Motion, Articular / Q000187:drug effects; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012720:Severity of Illness Index; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001688:Biological Products; C507763:IL1RN protein, human; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; D000069285:Infliximab; D000068800:Etanercept